Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study of Etoposide, Oxaliplatin and Capecitabine in Patients With Advanced HCC|
- Time to progression
|Study Start Date:||February 2006|
|Study Completion Date:||April 2007|
Open phase II study.
Response rate for the combination of etoposide, oxaliplatin and capecitabine given every 3 weeks on an outpatient basis.
Secondary endpoint are safety, time to progression and survival
Etoposide are administered intravenously 100 mg/m2 on day 1 and orally 200 mg/m2 on days 2 and 3.
Capecitabine (Xeloda) are administered 1000 mg/m2 twice daily with 12 hours interval for two weeks and one week off
Oxaliplatin are administered intravenously 100 mg/m2 on day 1 in each cycle as a 2 hours infusion.
One cycle is 3 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00351195
|Århus Sygehus, Dept. of Oncology|
|Århus, Denmark, 8000 C|
|Principal Investigator:||Ulrik Lassen, MD., PH.D.||Rigshospitalet, Dept. of Oncology|